Published in Gene Therapy Weekly, November 13th, 2003
Transgene will insert Antigen Express' Ii-suppression gene in its adenovirus-based cancer-immunotherapy products and evaluate the constructs in several animal models. The program is expected to proceed for up to 12 months after which time the companies have agreed to review the data in the view of further collaboration.
Robert E. Humphreys, MD, PhD, founder of Antigen Express, said, "Transgene has recognized expertise in the molecular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.